New Study Shows Glofitamab Plus Gemcitabine and Oxaliplatin is Superior for R/R DLBCL
A study presented at the European Hematology Association’s annual congress revealed that Glofitamab plus Gemcitabine and Oxaliplatin (GemOx) is superior to Rituximab-GemOx for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study, conducted by Dr. Jeremy Abramson and his colleagues from the Massachusetts General Hospital Cancer Center in Boston, examined the efficacy and safety of Glofit-GemOx versus R-GemOx in patients with R/R DLBCL after one or more prior lines of therapy.
The Study Findings
The researchers randomly assigned 274 patients in a 2:1 ratio to receive Glofit-GemOx or R-GemOx (183 and 91 individuals, respectively).
- In primary analysis, Glofit-GemOx showed a significant overall survival benefit compared to R-GemOx. Median overall survival was not reached for Glofit-GemOx versus nine months for R-GemOx at a median follow-up of 11.3 months.
- Independent review committee-assessed progression-free survival and complete remission rate demonstrated a significant benefit for Glofit-GemOx.
- Glofit-GemOx continued to demonstrate superior median overall survival, median progression-free survival, and complete remission rates at follow-up analysis conducted once all patients had completed therapy (cutoff date, Feb. 16, 2024; median follow-up, 20.7 months) versus R-GemOx.
Although adverse event rates were higher with Glofit-GemOx than R-GemOx, including grade 3 to 4 and grade 5 adverse events and serious adverse events, the rates were similar after adjustment for exposure differences.
“Glofitamab in combination with GemOx showed clinically significant improvement in overall survival, as well as key secondary end points, and the benefits were reinforced with an additional 11 months of follow-up,” said Dr. Abramson.
The Importance of DLBCL Research
DLBCL is a very aggressive type of non-Hodgkin lymphoma, and prognosis varies widely depending on the patient’s age, stage of disease and overall health. The survival rate for patients with relapsed or refractory DLBCL is very low, making the results of this study very promising.
Long-Tail Keywords for Subheadings
- Rituximab-GemOx for R/R DLBCL
- Glofit-GemOx versus R-GemOx
- DLBCL Research and Treatment
Originally Post From https://www.drugs.com/news/glofitamab-gemox-superior-rituximab-gemox-lymphoma-119975.html
